Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03823391
Recruitment Status : Completed
First Posted : January 30, 2019
Last Update Posted : March 26, 2021
Sponsor:
Information provided by (Responsible Party):
AbbVie

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a adalimumab active-controlled study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and efficacy following multiple intravenous (IV) injections of ABBV-3373 or multiple subcutaneous (SC) injections of adalimumab in participants with Rheumatoid Arthritis (RA) on background methotrexate (MTX). This study will also compare adalimumab with a synthetic control arm using historical placebo participants from similar trials to establish assay sensitivity.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis (RA) Drug: ABBV-3373 Drug: Placebo for ABBV-3373 Drug: Adalimumab Drug: Placebo for adalimumab Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects With Moderate to Severe Rheumatoid Arthritis
Actual Study Start Date : March 27, 2019
Actual Primary Completion Date : April 8, 2020
Actual Study Completion Date : August 26, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ABBV-3373 Followed by Placebo
Participants will be administered with ABBV-3373 and placebo for adalimumab every other week for 12 weeks. After 12 weeks, participants will receive placebo for adalimumab every other week until Week 22.
 Drug: ABBV-3373
ABBV-3373 is administered as intravenous (IV) injection

Drug: Placebo for adalimumab
Placebo for adalimumab is administered as subcutaneous (SC) injection
Experimental: Adalimumab
Participants will be administered with placebo for ABBV-3373 and adalimumab every other week for 12 weeks. After 12 weeks, participants will receive adalimumab every other week until Week 22.
 Drug: Placebo for ABBV-3373
Placebo for ABBV-3373 is administered as intravenous (IV) injection

Drug: Adalimumab
Adalimumab is administered as subcutaneous (SC) injection
Other Name: Humira


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in disease activity score (DAS) 28 (C-reactive protein [CRP]) from Baseline (BL) [ Time Frame: At Week 12 ]
    DAS is a combined index used to measure the disease activity in patients with RA.


Secondary Outcome Measures :
  1. Change in clinical disease activity index (CDAI) from BL [ Time Frame: At Week 12 ]
    The CDAI is a composite index for assessing disease activity based on the swollen/tender joint count along with patient and physician global assessment.

  2. Change in simplified disease activity index (SDAI) from BL [ Time Frame: At Week 12 ]
    The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count, patient and physician global assessment of disease activity and level of C-reactive Protein (CRP).

  3. Change in DAS (28 joints) (DAS28) erythrocyte sedimentation rate (ESR) from BL [ Time Frame: At Week 12 ]
    The DAS is a combined index used to measure the disease activity in patients with RA.

  4. Percentage of participants achieving a low disease activity (LDA) [ Time Frame: At Week 12 ]
    Low disease activity is defined as DAS28 (CRP) <= 3.2

  5. Percentage of participants achieving American College of Rheumatology (ACR) 50 [ Time Frame: At Week 12 ]
    ACR 50 response rate will be determined based on 50% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale (VAS)), Patient's Global Assessment of Disease Activity (PtGA), Physician's Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire Disability Index (HAQ-DI), or high-sensitivity C-reactive protein (hsCRP).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant has the clinical diagnosis of RA for > 3 months based on the 1987 American College of Rheumatology (ACR) classification criteria or 2010 ACR/European League against Rheumatism (EULAR) criteria.
  • Participant meets the following disease activity criteria: >= 4 swollen joints (based on 28 joint count) and >= 4 tender joints (based on 28 joint count) at Screening and Baseline visits and disease activity score (28 joints) (DAS28) C-reactive protein (CRP) >= 3.2 at Screening.
  • Participant has an incomplete response to MTX. Participants must have been on oral or parental MTX therapy >= 3 months and on a stable prescription of 15 to 25 mg/week (or >= 10 mg/week in participants intolerant of MTX at doses >= 15 mg/week) for >= 4 weeks prior to the first dose of study drug. Participant must be expected to be able to continue on stable dose of MTX for the duration of study participation.

Exclusion Criteria:

  • Participants previously exposed to adalimumab or other anti-tumor necrosis factor (TNF) biologics.
  • Participants previously exposed to non-anti-TNF biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for RA, with exception of participants exposed for less than 3 months and terminated not due to lack of efficacy or intolerability.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03823391


Locations
Show Show 30 study locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03823391    
Other Study ID Numbers: M16-560
2018-003053-21 ( EudraCT Number )
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: March 26, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by AbbVie:
Rheumatoid Arthritis (RA)
ABBV-3373
Adalimumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
 Autoimmune Diseases
Immune System Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents